PT  - JOURNAL ARTICLE
AU  - Pietro, R. Di
AU  - Basile, M.
AU  - Antolini, L.
AU  - Alberti, S.
TI  - Genetic drift versus regional spreading dynamics of COVID-19
AID  - 10.1101/2020.05.08.20095448
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2020.05.08.20095448
4099  - http://medrxiv.org/content/early/2021/01/24/2020.05.08.20095448.short
4100  - http://medrxiv.org/content/early/2021/01/24/2020.05.08.20095448.full
AB  - Background Current propagation models of COVID-19 are poorly consistent with existing epidemiological data and with evidence that the SARS-CoV-2 genome is mutating, for potential aggressive evolution of the disease.Methods We challenged regional versus genetic evolution models of COVID-19 at a whole-population level, over 168,089 laboratory-confirmed SARS-CoV-2 infection cases in Italy, Spain and Scandinavia. Diffusion data in Germany, France and UK provided a validation dataset of 210,239 additional cases.Results The mean doubling time of COVID-19 cases was 6.63 days in Northern versus 5.38 days in Southern Italy. Spain extended this trend of faster diffusion in Southern Europe, with a doubling time of 4.2 days. Slower doubling times were observed in Sweden (9.4 days), Finland (10.8 days), Norway (12.95 days). COVID-19 doubling time in Germany (7.0 days), France (7.5 days) and UK (7.2 days) supported the North/South gradient model. Clusters of SARS-CoV-2 mutations upon sequential diffusion across distinct geographic areas were not found to clearly correlate with regional distribution dynamics.Conclusions Acquisition of mutations, upon SARS-CoV-2 spreading across distinct geographic areas, did not distinctly associate to enhanced virus aggressiveness, and failed to explain regional diffusion heterogeneity at early phases of the pandemic. Our findings indicate that COVID-19 transmission rates associate to a sharp North/South climate gradient, with faster spreading in Southern regions. Thus, warmer climate conditions may not limit SARS-CoV-2 infectivity. Very cold regions may be better spared by recurrent courses of SARS-CoV-2 infection.Competing Interest StatementSaverio Alberti is founder and CEO of Oncoxx BiotechFunding Statementfunding was provided to this research by the university of Messina and Oncoxx BiotechAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical committee by the University of MessinaAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesall data referred to in the manuscript are available as needed